The Future...

Quote

Anonymous

Guest
Curious to what the direction at Mylan Specialty is? Is EpiPen going generic in 2015? Will we have a new product to promote before then? Future of Perforomist along with Combo coming out in 2016?

Consider this...Sunovian will be launching a combo close to that time, and hopefully not before us. What ever happened in the lawsuit outcome? What was the outcome? Mylan won the case but what were the details? It's brilliant on Mylans part when you think about it. If they get a % in royalties from Brovana and potentially the combo when it launches, they have Perforomist and Brovana coming in as profit, but only paying commissions to Perforomist.

Also, like any generic company...push, push, push until the end. But when Teva does launch another competitor in the market, if and when that happens, what is the next move? Will they treat it like any other generic product and move on? Will they still need a sales force. Is there another product waiting in the wings? Co-promotion?

And speaking of that...for Gods Sake, 9 and 4? Seriously? Here's an idea, why not allow us to sell products into our markets using all the data we have? I know in the "traditional" big pharma world you bulk the numbers up to look good for a potential co-promotion. But seriously, someone in upper management, grow some balls and come up with an original, outside the box sales plan that will attract another company.

So, what is the future at Mylan Specialty?
 






Anonymous said:
We are all dumber for reading this... The fukin direction is crystal clear make Epi a Billion dollar Rx and launch the combo... In that order dipsh!t!
Click to expand...



How's this going with the growth of the generic? What happens when Epi goes off patent and before the combo launches? Serious questions to think about...
 




Anonymous said:
you cant tell me you wake up in the morning and ACTUALLY get excited to...never mind. inept minds enjoy obtuse environments.
Click to expand...

The sales force is going to end up just like Basking Ridge Home Office!!! Extinct

Please see the pattern because your are all kidding yourself if u think HB will keep 300 reps to sell a $70mill LABA.

The building is burning, get out now if you a smart enough to see it for what it is!!!
 


No she is planning on selling the real epipen vs the exact same cheaper generic version when it launches. Also now that epipen is hitting 1 Billion dollars our bonus is going up by 3k! That's 1500 American dollars after taxes, who isn't motivated now?
 


Anonymous said:
The sales force is going to end up just like Basking Ridge Home Office!!! Extinct

Please see the pattern because your are all kidding yourself if u think HB will keep 300 reps to sell a $70mill LABA.

The building is burning, get out now if you a smart enough to see it for what it is!!!
Click to expand...


Yep, makes no sense unless they buy a company with branded products. How can anyone believe the BS that a generic wouldn't matter?
 


Anonymous said:
The sales force is going to end up just like Basking Ridge Home Office!!! Extinct

Please see the pattern because your are all kidding yourself if u think HB will keep 300 reps to sell a $70mill LABA.

The building is burning, get out now if you a smart enough to see it for what it is!!!
Click to expand...

DONT FORGET YOUR CYANKIT!!! THAT WAS ANOTHER WINNER! HA!!!
 


I'm not positive but I would say with 99% certainty that there has never been a blockbuster $1 Billion dollar product that was promoted with just 300 reps. Hell, I used to be on a sales team of 10,000 reps to promote a $2 billion product. There has never been a more efficient sales team in the world to produce this kind of result.

According to my math- we are averaging $3.33 million in Epipen sales per rep this year. Think about that number for a minute. At 8 calls per day and roughly 47 weeks of work per year after vacation and meetings- that is about 1,900 calls per year. Or about $1,700 in revenue per call. If you figure that the average rep costs Mylan $150,000 per year (all in with salary, bonus, car, insurance...), the cost per call is about $78. Lets get crazy and add $200 per call for other over head like management, advertising, support staff- $278 per call to get $1,700 in sales is a NICE return.

Even with this track record- If we don't have anything more to sell than Perforomist after
Epipen goes generic... the ax will fall. To stay on pace for our EPS target, we will need to slash costs to make up for the loss in revenue. You don't need an MBA to know that the easiest cost to cut is labor. That is why every large corporation down sizes with each down turn in revenue. They get the costs off the books and a bump in share price when they announce it.

Mylan leadership won't like doing it. At all. But when it is us or them to file into the unemployment line- it is a difficult but simple decision.
 












Seriously?? You think that 300 reps are solely responsible for the total sales of epipen? First of all, it had limited or no competition for a very long time. 2ndly, what is the Marketing spend? $50 million? Tons of DTC, commercials, digital, etc. Managed Markets access is probably the biggest contributor! 300 reps are a small part of the equation. Now do the math.


Anonymous said:
I'm not positive but I would say with 99% certainty that there has never been a blockbuster $1 Billion dollar product that was promoted with just 300 reps. Hell, I used to be on a sales team of 10,000 reps to promote a $2 billion product. There has never been a more efficient sales team in the world to produce this kind of result.

According to my math- we are averaging $3.33 million in Epipen sales per rep this year. Think about that number for a minute. At 8 calls per day and roughly 47 weeks of work per year after vacation and meetings- that is about 1,900 calls per year. Or about $1,700 in revenue per call. If you figure that the average rep costs Mylan $150,000 per year (all in with salary, bonus, car, insurance...), the cost per call is about $78. Lets get crazy and add $200 per call for other over head like management, advertising, support staff- $278 per call to get $1,700 in sales is a NICE return.

Even with this track record- If we don't have anything more to sell than Perforomist after
Epipen goes generic... the ax will fall. To stay on pace for our EPS target, we will need to slash costs to make up for the loss in revenue. You don't need an MBA to know that the easiest cost to cut is labor. That is why every large corporation down sizes with each down turn in revenue. They get the costs off the books and a bump in share price when they announce it.

Mylan leadership won't like doing it. At all. But when it is us or them to file into the unemployment line- it is a difficult but simple decision.
Click to expand...
 




Anonymous said:
No she is planning on selling the real epipen vs the exact same cheaper generic version when it launches. Also now that epipen is hitting 1 Billion dollars our bonus is going up by 3k! That's 1500 American dollars after taxes, who isn't motivated now?
Click to expand...

Exactly. If you're fortunate enough to have a DEY Rep from pre 2007 around, ask them about the history of Duoneb. The managers either lied or didn't tell the Reps the truth and we found out online that Duoneb went generic. The managers were so upset that we found out! We were to sell the 2 in 1 bennys to the end. Then, DEY began making a generic, sold to make revenue off of that then made the reps 'pay' for not beating the generic….Accuneb…died and Epi just began to get it's first competitor with TwinJect. Many of us had to move on. Duoneb was the business. Think strategically-bc the company sure is… best of luck.
 


Anonymous said:
Exactly. If you're fortunate enough to have a DEY Rep from pre 2007 around, ask them about the history of Duoneb. The managers either lied or didn't tell the Reps the truth and we found out online that Duoneb went generic. The managers were so upset that we found out! We were to sell the 2 in 1 bennys to the end. Then, DEY began making a generic, sold to make revenue off of that then made the reps 'pay' for not beating the generic….Accuneb…died and Epi just began to get it's first competitor with TwinJect. Many of us had to move on. Duoneb was the business. Think strategically-bc the company sure is… best of luck.
Click to expand...

so are you implying that perforomist could go away or be ignored further? this brand is what gets people to win president club.
 





Write your reply...
Top Bottom
Back
Quote